
Low-Dose Apixaban Best for Long-Term Use in Cancer
CHICAGO — Extended therapy with reduced-dose apixaban is just as effective as the high dose in preventing recurrent venous thromboembolism (VTE) in patients with active cancer who completed at least 6 months of anticoagulant treatment after a clot, and …